Last updated on December 2019

Study of Safety Reactogenicity and Immunogenicity of GlaxoSmithKline's (GSK)Respiratory Syncytial Virus (RSV)Maternal Unadjuvanted Vaccine in Healthy Pregnant Women (Aged 18 to 40 Years) and Their Infants


Brief description of study

The purpose of this study is to evaluate the safety and immune response to a single intramuscular (IM) dose of GSK Biologicals' investigational RSV maternal vaccine (RSVPreF3) in healthy pregnant women 18-40 years of age and in infants born to vaccinated mothers.

Clinical Study Identifier: NCT04126213

Find a site near you

Start Over

GSK Investigational Site

Huntington Park, CA United States
  Connect »

GSK Investigational Site

Nampa, ID United States
  Connect »

GSK Investigational Site

Metairie, LA United States
  Connect »

GSK Investigational Site

Gulfport, MS United States
  Connect »

GSK Investigational Site

Saint Louis, MO United States
  Connect »

GSK Investigational Site

Englewood, OH United States
  Connect »

GSK Investigational Site

Beaumont, TX United States
  Connect »

GSK Investigational Site

Fort Worth, TX United States
  Connect »

GSK Investigational Site

Johnson City, NY United States
  Connect »

GSK Investigational Site

Houston, TX United States
  Connect »

GSK Investigational Site

South Brisbane, Australia
  Connect »

GSK Investigational Site

Wellington, New Zealand
  Connect »